Search Results
Your search for ,WHo matches 20837 pages
Showing 301 - 350New Report on Breast Reconstruction Preferences Among African American Women
For African American patients undergoing mastectomy, the risk of complications and the postoperative appearance of the breast are among the important drivers of preferences about breast reconstruction, according to a new report published by Shammas et al in Plastic and Reconstructive Surgery....
Model to Identify Patients With Clinical High-Risk Early Breast Cancer Who May Avoid Escalated Adjuvant Therapy
As reported in the Journal of Clinical Oncology, Bidard et al developed a model that may identify a subgroup of patients with clinical high-risk estrogen receptor (ER)-positive/HER2-negative early breast cancer who might derive no additional distant recurrence benefit from escalation of adjuvant...
How the AI-Powered ASCO® Guidelines Assistant Is Improving Clinical Decision-Making
This past May, ASCO announced its collaboration with Google Cloud to launch the ASCO® Guidelines Assistant, a new interactive tool that allows clinicians to quickly access ASCO’s evidence-based clinical guidelines to facilitate critical clinical decision-making. Developed with Google Cloud’s Vertex ...
Study Shows That After Early Breast Cancer Diagnosis, Risk of a Second Cancer Is Low
For individuals diagnosed with early breast cancer, the long-term risk of developing a second primary cancer is low—around 2% to 3% greater than the general population)—according to findings published by McGale et al in The BMJ. The researchers say this information can help reassure many breast...
Public Awareness of HPV, HPV Vaccine, and the Association of HPV With Cancer
In a U.S. state-level study reported as a research letter in JAMA Oncology, Garg et al found that awareness of human papillomavirus (HPV), HPV vaccination, and the association between HPV infection and development of cancers was “overwhelmingly low.” As stated by the investigators, “Each year, an...
IDO1 Inhibition Mitigates Diet-Induced Risk of Cancer-Associated VTE in Preclinical Models
Patients with cancer who have a diet high in tryptophan, or protein-rich foods, have an increased risk for developing cancer-associated venous thromboembolism, according to preclinical findings published in Blood Advances. This increased risk could potentially be mitigated by treatment with an...
Addition of Sintilimab to Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer
In a Chinese single-center phase II trial (SPRING-01) reported in The Lancet Oncology, Tian et al found that the addition of the PD-1 inhibitor sintilimab to chemotherapy following short-course radiotherapy as part of total neoadjuvant treatment significantly improved the pathologic complete...
FDA Approves BTK Inhibitor for ITP
The U.S. Food and Drug Administration (FDA) has approved rilzabrutinib (Wayrilz), a Bruton’s tyrosine kinase (BTK) inhibitor, for adults with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The approval was based on the pivotal LUNA ...
Do Breast and Gynecologic Cancers Contribute to Job Resignation in Working Women?
In a matched-cohort study reported in JAMA Network Open, Iwakura et al found that women with breast or gynecologic cancer had a higher risk of job resignation compared with their unaffected counterparts, especially among those who were older, had lower income, or had a history of depression. “These ...
Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With AML
Based on the results of a single-center phase II trial published by Bhatt et al in the American Journal of Hematology, pretreatment geriatric assessment in older adults with acute myeloid leukemia (AML) appeared to be feasible, to identify several functional impairments, to help guide the selection ...
Understanding Accelerated Aging in Survivors of Childhood Cancers
Each year in the United States, nearly 16,000 children and adolescents between the ages of birth and 19 are diagnosed with cancer.1 And although survival rates have greatly improved for many types of childhood cancers, with more than 8 in 10 children and adolescents surviving at least 5 years after ...
Gastrointestinal Tumor Microbes May Predict Prognosis and Therapeutic Response
Microbes inside cancerous tumors can influence the spread of disease and the effectiveness of treatment, and those roles make them appealing targets for new therapies. Tumor microbiota–based tools could also help identify high-risk patients and those most susceptible to metastases, and possibly be...
Conversion of Unresectable Into Resectable Pancreatic Cancer: Chemoradiotherapy vs Chemotherapy
In a German phase III trial (CONKO-007) reported in the Journal of Clinical Oncology,1Rainer Fietkau, MD, of the Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany, and colleagues found that adding chemoradiotherapy to chemotherapy vs...
Mifamurtide Plus Chemotherapy for Nonmetastatic High-Grade Osteosarcoma
In a pooled analysis of the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) trials reported in the Journal of Clinical Oncology, Palmerini et al found evidence of activity with the addition of mifamurtide to chemotherapy in patients with nonmetastatic high-grade osteosarcoma...
How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting
After 2 decades of practicing medicine across multiple disciplines and health systems, I’ve witnessed the dramatic transformation of patient-physician interactions, and none more dramatic than what I’m seeing in this era of artificial intelligence (AI) and its impact on cancer care. Early in my...
Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy
Patients with intermediate-stage hepatocellular carcinoma who received a vaccine of dendritic cells in addition to transarterial chemoembolization (TACE) and preconditioning cyclophosphamide experienced longer progression-free survival than those who received cyclophosphamide and TACE alone. The...
Identifying CNS Tumors With Multianalyte Cerebrospinal Fluid Test
A novel, multianalyte test has been developed to identify central nervous system cancers from small samples of cerebrospinal fluid (CSF). In findings published in Cancer Discovery, the study authors reported that the test, called CSF-BAM, achieved a sensitivity of 81% and a specificity of 100%....
Survey Finds Discordance Between Treatment Preferences and Clinical Care for Advanced Cancer
Patients with advanced cancer reported in survey responses that their treatment often focused on optimizing longevity over maintaining comfort and quality of life, despite their goals that prioritized the opposite, according to study results published in Cancer. Additionally, the findings...
Association of Germline Pathogenic/Likely Pathogenic Mutations and Subsequent Neoplasms in Childhood Cancer Survivors
In an analysis from the Children’s Oncology Group ALTE03N1 Study reported in the Journal of Clinical Oncology, Zhou et al found a fourfold increased risk of subsequent neoplasms (SNs) among childhood cancer survivors with germline pathogenic/likely pathogenic (P/LP) mutations. Study Details The...
What We Wish We Knew During Fellowship
July marks a significant transition for many professionals, particularly those beginning structured training programs on July 1. This article is designed to support new and current hematology-oncology fellows and trainees in making the most of their training experience. Although not all suggestions ...
ASCO Thanks Richard L. Schilsky, MD, FACP, FSCT, FASCO, for His Vision and Leadership of TAPUR
ASCO extends its thanks and appreciation to Richard L. Schilsky, MD, FACP, FSCT, FASCO, for his decade of leadership and dedication as the inaugural Principal Investigator of the groundbreaking Targeted Agent and Profiling Utilization Registry (TAPUR) Study. The ASCO-sponsored TAPUR study is a...
Case 3: Cardiac Risk Stratification
This is Part 3 of Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Kelly McCann, Hope Rugo, and Avirup Guha discuss a challenging...
Can Baseline Kidney Function Predict Chronic Kidney Disease After Cisplatin Treatment?
A population-based prognostic study published in JAMA Oncology found cisplatin treatment to be associated with a predictable decrease in the estimated glomerular filtration rate. According to Grant et al, their findings place patients with lower baseline kidney function at the highest risk for...
BWEL Weight-Loss Trial Reports Success for Patients With Breast Cancer at 1-Year Mark
Patients with stage II or III breast cancer who participated in a remote weight-loss intervention program lost an average of 4.7% of their baseline body weight after 1 year, whereas those in the education-only control group gained an average 1% of their baseline weight, according to a recent report ...
Adding Everolimus to Chemotherapy Reduces Risk for Advanced Triple-Negative Breast Cancer
The addition of everolimus to standard carboplatin chemotherapy led to a 52% reduction in the risk of disease progression or death compared with carboplatin alone in patients with advanced triple-negative breast cancer, according to the results of a randomized phase II trial published in Breast...
Rare Secondary Cancer After CAR T-Cell Therapy Successfully Treated, Case Report Shows
In a case presentation published in The New England Journal of Medicine, targeted treatment was successful for chimeric antigen receptor (CAR)-positive peripheral T-cell lymphoma developed after CAR T-cell therapy for multiple myeloma. Using advanced genomic, phenotypic, and functional profiling...
Bacterial Decolonization to Manage Acute Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma
Based on the results of a single-center phase III Chinese trial, which were published by Liao et al in JAMA Oncology, bacterial decolonization therapy with the antibiotic mupirocin may be an effective and cost-efficient strategy for alleviating severe acute radiation-induced oral mucositis in...
Smoldering Multiple Myeloma: How the Guidance Is Changing
Clinical trials have sought to determine the benefit of treating the precursors of multiple myeloma, but as the phenotypes and genomics of this entity are becoming better delineated, the wisdom of early intervention has remained confusing for clinicians. At the 2025 Debates and Didactics in...
Advancing Geriatric Oncology: A Personal and Professional Journey
I would like to begin by sharing a bit of my journey in geriatric oncology. Often, we do not hear the origin stories behind our professional paths, and I believe it is important to reflect on them. I have spent my entire academic career at Wake Forest University School of Medicine, where I arrived...
Can Beta Blockers Help Halt the Progression of Triple-Negative Breast Cancer?
Researchers have identified a molecular biomarker in triple-negative breast cancers that may inform when beta blockers can play a role in “switching off” tumor progression. These findings were published by Lam et al in Science Signaling. When stress hormones are released by the body’s nervous...
Nivolumab Plus RP1 Shows Durable Responses in Advanced Melanoma After PD-1 Inhibitor Resistance
Nivolumab in combination with RP1 (vusolimogene oderparepvec), a herpes simplex virus type 1–based oncolytic immunotherapy, showed activity in patients with advanced melanoma who experienced disease progression on standard anti‒PD-1‒based immunotherapy, according to findings from the phase I/II...
Treatment Rechallenge After Interstitial Lung Disease Related to T-DXd: Is It Safe?
Rechallenge with the HER2-directed antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) after grade 1 interstitial lung disease (ILD) appeared to be safe in a diverse real-world population, including many patients with breast cancer, as presented during the 2025 ASCO Annual Meeting.1 The ...
Rural and Urban Differences in Prostate Cancer Recurrence
In a study reported in JAMA Network Open, Balmaceda et al found that rural patients in North Carolina with newly diagnosed prostate cancer were more likely to experience biochemical recurrence than were urban patients. Study Details This cohort study used data from the North Carolina Prostate...
Friends of Cancer Research Advances Work to Improve Interpretation of Interim OS Data in Oncology Trials
Friends of Cancer Research (Friends) launched the next phase of an initiative to improve how to interpret interim overall survival (OS) data in oncology clinical trials. Building on discussions during the Friends 2024 Annual Meeting, this new effort focuses on developing practical frameworks and...
Patient and Health-Care Professional Groups Express Support for Bipartisan Clinical Trial Bill
More than 100 organizations representing millions of patients with serious health conditions and health-care professionals sent a letter to Congress expressing their strong support for the Clinical Trial Modernization Act. Introduced in the House of Representatives in May 2025 by Reps. Raul Ruiz...
New Recommendations Released for Managing Aromatase Inhibitor–Induced Bone Loss
A group of experts from seven professional societies have published a joint position statement in the Journal of Bone Oncology on the management of aromatase inhibitor–associated bone loss (AIBL) as a guide for osteoporosis specialists and oncologists. This position statement acts as an update on...
Neoadjuvant Osimertinib in the Perioperative Setting for Resectable, EGFR-Mutated NSCLC
“Neoadjuvant treatment with osimertinib, with or without chemotherapy, should be considered when planning treatment for patients with resectable, EGFR-mutated, stage II to IIIB non–small cell lung cancer [NSCLC],” according to Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center and ...
Underlying Mechanisms of Chemoresistance in AML
Researchers have discovered that an isoform of the transcription factor RUNX1 orchestrates chemoresistance in patients with acute myeloid leukemia (AML), according to findings published in Blood Cancer Discovery. They identified that the long-isoform RUNX1C's connection to BTG2 may enable cellular...
Effect of Hippocampal Avoidance in Prophylactic Cranial Irradiation in SCLC
In a phase II/III trial (NRG-CC003) reported in the Journal of Clinical Oncology, Gondi et al found that hippocampal avoidance (HA) in prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC) did not improve delayed recall failure but was associated with benefits in...
Treatment-Resistant Melanoma: Novel Checkpoint Inhibitor Combination
New research published by Phadke et al in the Journal for ImmunoTherapy of Cancer found that adding a third immune-targeting drug to existing therapies may help to shrink tumors in laboratory models of treatment-resistant melanoma. Although immunotherapeutics have improved survival for many...
Endocrine Therapy With Aromatase Inhibitor for Postmenopausal Women With Breast Cancer
In a patient-level meta-analysis reported in The Lancet, Braybrooke et al of the Early Breast Cancer Trialists’ Collaborative Group found that adding subsequent years of aromatase inhibitor treatment (AIT) for women with early estrogen receptor–positive breast cancer who had already received 5...
Case 2: Patient With Myelofibrosis and Anemia
This is Part 2 of Optimizing Management of Myelofibrosis: Balancing Watchful Waiting and Early Action, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Raajit Rampal, Prithviraj Bose, and Jeanne Palmer discuss the treatment of a ...
Case 1: Patient With Newly Diagnosed Post-PV Myelofibrosis
This is Part 1 of Optimizing Management of Myelofibrosis: Balancing Watchful Waiting and Early Action, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Raajit Rampal, Prithviraj Bose, and Jeanne Palmer discuss the treatment of...
PSMA PET/CT and Salvage Radiotherapy in Recurrent Prostate Cancer
Use of prostate-specific membrane antigen (PSMA) PET/CT before undergoing salvage radiotherapy was associated with an improved overall survival and biochemical recurrence–free survival compared those who did not receive PSMA PET/CT scanning in male patients with biochemically recurrent prostate...
Patient Awareness of Pharmacogenomic Testing Remains Low, ACS CAN Survey Reports
Less than half of responding patients with cancer were previously familiar with pharmacogenomic testing and its possible benefits, according to the results of a survey conducted by the American Cancer Society Cancer Action Network (ACS CAN). Of the patients who did know about pharmacogenomic...
New Report Supports Overhaul of Cancer Drug Dosing
A new study calls for a paradigm shift in how cancer drug dosages are determined, concluding that the long-standing practice of using the “maximum tolerated dose” (MTD) may be outdated, harmful to patients, and ill-suited for modern cancer therapies. “The Totality of the Evidence: Optimizing Dosage ...
Studies on EGFR Mutations and NRG1 Fusions Included in ASCO NSCLC Living Guideline Update
ASCO has issued a new update to its living guideline on treatment of stage IV non–small cell lung cancer (NSCLC) with driver alterations based on two recent studies.1 The update, which amends the most recent version published in February 2025, includes a discussion of osimertinib therapy options in ...
Emerging PD-1 Inhibitor Plus Chemotherapy Shows Efficacy in Second-Line Classical Hodgkin Lymphoma
The addition of the PD-1 inhibitor sintilimab to ICE (ifosfamide, carboplatin, and etoposide) chemotherapy appeared to significantly improve the complete remission rate and showed a trend toward improved progression-free survival in second-line classical Hodgkin lymphoma, according to Yuankai Shi,...
Are Postmastectomy Implant-Based Breast Reconstructions Associated With Lymphomas of the Breast?
The results of a cohort study published in JAMA Network Open revealed an epidemiologic association between postmastectomy implant-based breast reconstruction for any breast tumor and both B- and T-cell non-Hodgkin lymphomas of the breast. According to Kinslow et al, this includes diffuse large...
Tafasitamab Combined With Lenalidomide and Rituximab Improved Outcomes in Relapsed or Refractory Follicular Lymphoma
Adding tafasitamab-cxix, an anti-CD19 monoclonal antibody, to lenalidomide and rituximab significantly prolonged progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented at the 2025 European Hematology Association (EHA) Congress.1 Results...
